CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate DevelopmentsBusiness Wire • 12/28/22
CEL-SCI'S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care TreatmentBusiness Wire • 10/17/22
CEL-SCI's Multikine - Potential 21st Century Game-Changing Cancer Drug On The HorizonSeeking Alpha • 09/30/22
CEL-SCI'S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck CancerBusiness Wire • 09/12/22
CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.govBusiness Wire • 08/19/22
CEL-SCI Reports Fiscal 2021 Financial Results and Clinical & Corporate DevelopmentsBusiness Wire • 12/22/21
CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing FacilityBusiness Wire • 10/22/21
CEL-SCI: Pivotal Clinical Trial Results Point To Upside For Patients And InvestorsSeeking Alpha • 07/14/21
